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ABSTRACT  
Intra-vaginal route of administration is a route of administration where the dosage form is applied vaginally for the convenient release of the 
dosage form and for better therapeutic action of the medicament, it is usually used in HIV patients. Vaginal route is been used as a traditional 
delivery system used for the conventional delivery of several locally acting drugs like antimicrobial agents. The various types of formulations as 
well as the dosage forms are available for intra-vaginal drug delivery system such as tablets gels vaginal rings etc. the disease’s such as HIV or 
other diseases caused into the vaginal area due to causative agents like bacteria fungi etc.  For efficient vaginal delivery of drugs, the delivery 
system should reside at the site of infection for a prolonged period of time.  
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INTRODUCTION: 
Vagina is route of administration for   Variability in drug 
absorption related with contraceptives, anti-fungal, and 
menstrual cycle, menopause and antimicrobials. It is used for 
the   achievement of local or for systemic   absorption. The 
vaginal wall is very well   suited for the absorption of drugs 
for   Some drugs are sensitive at vaginal pH systemic use. As 
it contains a vast network   of blood vessels. 
Infection with HIV remains an incurable condition. The 
highest rate of HIV transmission is through the exposure of 
the vaginal mucosal surface to HIV during sexual intercourse.  
Microbicides circumvent many of the immunological 
difficulties associated with HIV vaccine development and 
make topical formulations a more realistic goal, especially in 
the short term   The most promising strategy currently being 
pursued is the utilization of intravaginal delivery systems for 
microbicides.  The vaginal route has been rediscovered as a 
potential route for systemic delivery of various 
therapeutically important drugs avoid first pass metabolism. 
However, fruitful delivery of drugs through the vagina 
remains a challenge because of poor absorption of some 
drugs across vaginal epithelium. The various factors like 
vaginal physiology, age of patient, menstrual cycle are 
affecting the rate of drug absorption after vaginal 
administration. The future of vaginal drug delivery lies in the 
bioadhesive tablets, liposomes, niosomes and microparticles, 
which although relatively new and show great promise in 
providing truly controlled delivery of drugs. 
 
TYPES OF DOSAGE FORMS USED: 
 Vaginal tablets 
 Vaginal Gels 
 Vaginal creams 
 Vaginal rings 
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 Suppositories. 
Vaginal gels and tablets have rapid release rates which, for 
effective use, ultimately require administration several times 
a day. Vaginal rings have adequate release rates but have 
only been formulated for preventing the transmission of HIV 
and as a contraceptive. The most widely used semi-solid 
preparations for vaginal drug delivery include creams, 
ointments, and gels. 
Creams and Gels 
To date the greatest number of intravaginal drug delivery 
systems for microbicides, by far, is in the form of creams or 
gels. Although commonly used for the topical intravaginal 
delivery of microbicides, these systems are messy, 
uncomfortable and may not provide an exact dose due to 
non-uniform distribution and leakage 
Tablets and Suppositories 
A large number of intravaginal delivery systems are also 
available in the form of tablets or suppositories. Some 
authors use the terms pessaries and suppositories 
interchangeably and consider vaginal tablets as a separate 
dosage form. These formulations are designed to melt in the 
vaginal cavity and release the microbicide over several 
hours. Suppositories are most commonly used to administer 
drugs for cervical ripening prior to child birth and for local 
delivery of various drugs. Vaginal tablets may contain 
binders, disintegrants and other excipients that are used to 
prepare conventional oral tablets. Mucoadhesive polymers 
are sometimes used in tablet formulations to increase the 
vaginal residence time of the microbicide been delivered. 
Other vaginal tablet-like formulations are extrapolations of 
silicone-based vaginal rings. Research groups have studied 
the release of microbicides from silicone matrices. Release 
studies were performed in vitro for up to 1 year and in vivo in 
rabbits for up to 52 days. Both in vitro and in vivo studies 
showed consistent release profiles over time, showing that 
microbicide delivery is controlled by diffusion from the 
silicone delivery device and was not limited by absorption 
through the vaginal epithelium. 
Vaginal Rings 
Vaginal rings are circular ring-type drug delivery devices 
designed to release microbicides in a controlled manner after 
insertion. The advantages of such a device are that it can be 
controlled by the user; does not interfere with coitus and 
allows for the continuous delivery of microbicidal 
compounds. In simple vaginal rings, the microbicide is 
homogeneously dispersed within a polymeric ring with the 
surface of the ring releasing the microbicide faster than the 
inner layers. The key challenge in development of these 
systems is finding the optimum dose that will deliver the 
least amount of microbicide necessary to ensure protection. 
Advances have been made on the original two-layer ring 
system by adding a third, outer, rate controlling drug-free 
elastomer layer to minimize the drug concentration spike.
 
 
Mechanism: 
 
 
Benefits and uses. 
 It reduces vaginal burning and vaginal infection. 
 It reduces vaginal itching and vaginal discharge. 
 Treatment of vaginal dryness. 
 Treatment of HIV 
 Treatment of yeast infection. 
 Contraceptives 
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TABLE 1: Some of the experimented vaginal drug delivery system9 . 
Therapeutic drug Intended use Dosage form Animal model Comments 
Nonoxynol-9 Spermicide/topica l 
contraceptive 
Gel,foam,cream Rabbit Detergent type spermicide, 
irritation and increased risk 
of infection 
Miconazole nitrate Anti-fungal Cream, suppository, 
swelling controlled release 
system 
Invitro  
Prostaglandin E2 Cervical ripenig Crosslinked PEG hydrogel, 
suppository 
invitro Onset of labor not always 
predictable 
Lactobacilli strains Urogenital tract 
infections 
Bi-layered tablet invitro Restoration of normal 
vaginal flora, good bacterial 
viability in tablets 
Progestin, 
levonorgestrel , 
orethindrone acetate 
contraceptives Vaginal ring Human Uterine bleeding, hormonal 
side effects, expulsions 
estradiol Harmone 
replacement 
therapy 
Vaginal ring Human Risk of endometrial 
proliferation 
Relaxin Cervical ripenig Gel  Human Decreased incidence of 
cesarean deliveries, reduced 
maternal-fetal morbidity 
LHRH Hormone 
dependent 
mammary tumors, 
fertility control 
Supposistory  Rat Suppress secretion of 
ovarian steroids 
Leuprolide Ovulation inducing 
activity 
Solution suppository, Rat Activity increased by 5 
times with addition of 
absorption enhancers 
Insulin Diabetis mellitus Solution, gel Rabbit, rat  Low bioavaliabilty 
 
ADVANTAGES 
 Simple to manufacture, cost effective and easy to apply 
thus facilitating patient compliance 
 Non-irritative and free from producing any physical 
discomfort 
 Provide immediate and sustained protection by 
releasing the microbicide in a controlled manner over a 
prolonged period of timeSolution was transferred into 
amber colored bottle and sealed till further use and 
resulting solutions were sterilized by autoclave at 
121°C for 20 min at 15 psi. 
 Have suitable vaginal retention and distribution 
 Be versatile against various pathogens encompassing 
STIs and HIV 
METHOD OF PREPARATION: 
TABLETS:- 
 the vaginal tablets were prepared by direct 
compression and direct blending. 
 the ingredients were weighed and passed through sive 
no # 20 ASTM . 
 the materials sived was blended into double cone 
blender at 15 RPM. 
 The blended materials were again sifted through #30 
ASTM sieve. 
 these shifted materials was again blended into the 
blender for 15 min at 15 RPM. 
 the lubricant is sieved through sive no #60 ASTM and 
addead to above blended mixture and again blended at 
15 RPM. 
 the direct compression was done for the formation of 
the vaginal tablet. 
GELS: 
1. The cold method was used to prepare the vaginal insitu 
gel. 
2. The preferd quantity of drug is weighed and dissolve in 
saline phospate buffer in aseptic conditions. 
3. Preservatives was added at same time. 
4. Meanwhile the mixtures of polymers was kept aside for 
24 hours for proper mixing. 
5. Next the drug and polymeric solution was mixed 
properly and the intended quantity was added to the 
isotonic solution . 
6. Solution was transferred into amber colored bottle and 
sealed till further use and resulting solutions were 
sterilized by autoclave at 121°C for 20 min at 15 psi. 
CONCLUSION: 
Vaginal preparations, although generally perceived as safer 
most still associated with number of problems including 
multiple days of dosing, dripping, leakage and messiness, 
causing discomfort to users and expulsion due to the self-
cleansing action of the vaginal tract. These limitations lead to 
poor patient compliance and failure of the desired 
therapeutic effects. For efficient vaginal delivery of drugs, the 
delivery system should reside at the site of infection for a 
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prolonged period of time. The vaginal prepartions are 
explained in short for their convenient use. 
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